Courtagen Life Sciences Blog

15 New Panels Address Ciliopathy, Endocrinology, Neuromuscular, Bone Density, and Connective Tissue

Posted by Courtagen Staff on May 15, 2017 3:31:37 PM

Our test menu has expanded, again! This month, we have added 11 new Spotlight™ panels, three new Focus™ panels, and one new Comprehensive panel, across multiple disorder types. 

Read More

Topics: Genetic Testing, Company News, endocrinology, Multi-System

11 New Spotlight™ Panels added to test menu

Posted by Courtagen Staff on Apr 6, 2017 10:15:00 AM

This month, we are happy to announce we have added another 11 tests to our growing catalog of Courtagen Spotlight™ Panels. These small (3 to 50 genes) panels provide clinicians with a targeted approach to genetic testing, and are best used when a patient's symptomatology is discernible. Each Spotlight Panel contains addresses a group of disorders with overlapping symptoms, making test selection clear and straightforward.

Read More

Topics: Genetic Testing, Company News

10 New Spotlight™ Panels for Targeted Genetic Testing

Posted by Courtagen Staff on Mar 14, 2017 10:37:00 AM

We are happy to announce the addition of 10 new tests to our Spotlight™ Panel line, which provides clinicians a targeted approach to genetic testing when a patient's symptomatology is discernible. Each Spotlight Panel contains between approximately 3 to 50 genes selected to address a group of disorders with overlapping symptoms, making test selection clear and straightforward.

Read More

Topics: Genetic Testing, Company News

Courtagen Receives Notice of Allowance for a Genetically Targeted Pain Therapy Patent

Posted by Courtagen Staff on Feb 24, 2017 11:45:04 AM

We are excited to announce that we received a Notice of Allowance from the United States Patent and Trademark Office for a patent that uses a personalized medicine approach to match genetic markers for chronic pain with therapeutic drugs, including the cannabis-derived compound cannabidiol.

Read More

Topics: Genetic Testing, Cannabis, Chronic Pain

New Spotlight Panels are Here!

Posted by Courtagen Staff on Feb 7, 2017 12:20:24 PM

We are happy to announce that we have added 17 new gene panels to our Spotlight line of tests. These new tests will expand our menu by 65%, offering new testing options in neurology, endocrinology, epilepsy, developmental delay, mitochondrial disease, and other disease areas.

Read More

Topics: Epilepsy, Genetic Testing, Genetics, endocrinology

Genetic Testing Helps Patient Beat 10 Year Battle with Seizures

Posted by Courtagen Staff on Jan 13, 2017 2:42:20 PM

 

Read More

Topics: Epilepsy, Genetic Testing, Success Story

Pathogenic, Benign, or Uncertain: Evaluating Genetic Variants

Posted by Cheryl Scacheri, MS, LGC on Jan 5, 2017 2:03:00 PM
Read More

Topics: Genetic Testing, Genetics

The Power of Parents: How Parent Samples Improve Genetic Testing Results

Posted by Cheryl Scacheri, MS, LGC on Dec 8, 2016 10:45:00 AM

At Courtagen, we offer DNA testing that uses next generation sequencing to diagnose neurological, mitochondrial, and other disorders. Because the brain and mitochondria are so complex, many of our panels have a thousand genes or more.

Read More

Topics: Seizure Disorders, Mitochondrial Disorders, Genetic Testing, Developmental Delay

ALG13: X-Linked Gene Causes Severe Neurological Disease in Females

Posted by Stacey Wong, MS, LCGC on Nov 22, 2016 9:04:00 AM

After performing diagnostic testing on several thousand patients with seizure disorders, Courtagen's Clinical Team has described a variant in the ALG13 gene that directly causes infantile spasms, intellectual disability, and severe neurologic disease.

Read More

Topics: Epilepsy, Seizure Disorders, Genetic Testing

How Courtagen's Genetic Tests Differ from 23andMe

Posted by Cheryl Scacheri, MS, LGC on Oct 26, 2016 3:46:02 PM
Read More

Topics: Genetic Testing, Genetics